Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream inf ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback